Aprotinin in deep hypothermic circulatory arrest
The Annals of Thoracic Surgery, ISSN: 0003-4975, Vol: 68, Issue: 1, Page: 278-286
1999
- 21Citations
- 11Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Early experience with aprotinin in deep hypothermic circulatory arrest (DHCA) raised alarm about hazards associated with its use. Based on what little is known about possible mechanistic interactions between hypothermia, stasis, and aprotinin, there is no evidence that aprotinin becomes unusually hazardous in DHCA. Excessive mortality and complication rates have only been reported in clinical series in which the adequacy of heparinization is questionable. Benefits associated with use of aprotinin in DHCA have been inconsistently demonstrated. The only prospective, randomized series showed significant reduction in blood loss and transfusion requirements. Use of aprotinin in DHCA should be based on the same considerations applied in other cardiothoracic procedures.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0003497599005184; http://dx.doi.org/10.1016/s0003-4975(99)00518-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0032776365&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/10421168; https://linkinghub.elsevier.com/retrieve/pii/S0003497599005184; http://linkinghub.elsevier.com/retrieve/pii/S0003497599005184; http://api.elsevier.com/content/article/PII:S0003497599005184?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0003497599005184?httpAccept=text/plain
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know